FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB A | PPF | ROV | Ά |
|-------|-----|-----|---|
|-------|-----|-----|---|

| OMB Number: | 3235-0287 |
|--------------------------|-----------|
| Estimated average burden | |
| hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | of decition 30(ii) of the investment company Act of 1340 | |
|--|----------|--|--|
| Name and Address of Reporting Person* Radov A. Jeffrey | | 2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX] | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner |
| | | | Officer (give title Other (specify |
| (Last) (First) 8 WALWORTH AVENUE | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 10/29/2018 | below) below) |
| (Street) SCARSDALE NY (City) (State) | 10583 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| , (| 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | Securities Beneficially Owned | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--------------|--|---|-----------------------------|---|--|---------------|-------|----------------------------------|---|---|
| | | | Code | v | Amount | (A) or (D) | Price | (Instr. 3 and 4) | | (IIISU. 4) |
| Common Stock | | | | | | | | 12,500 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | | | | | | | | | 44 Natura | | | | |
|--|---|--|---|---------------------------------|---|--|-----|--|--------------------|---|--|--|--|---|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transac Code (li 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | (Instr. 4) | | |
| Stock Option | \$4.7 | | | | | | | (1) | 02/09/2022 | Common Stock | 30,000 | | 30,000 | D | |
| Stock Option | \$4.7 | | | | | | | (2) | 12/07/2022 | Common Stock | 5,000 | | 5,000 | D | |
| Stock Option | \$4.7 | | | | | | | (3) | 10/04/2023 | Common Stock | 12,500 | | 12,500 | D | |
| Stock Option | \$4.7 | | | | | | | (4) | 02/18/2024 | Common Stock | 25,000 | | 25,000 | D | |
| Stock Option | \$4.7 | | | | | | | (5) | 10/23/2024 | Common Stock | 50,000 | | 50,000 | D | |
| Stock Option | \$4.7 | | | | | | | (6) | 09/04/2025 | Common Stock | 115,500 | | 115,500 | D | |
| Stock Option | \$3.73 | | | | | | | (7) | 06/10/2026 | Common Stock | 128,000 | | 128,000 | D | |
| Stock Option | \$3.35 | | | | | | | (8) | 06/23/2027 | Common Stock | 125,000 | | 125,000 | D | |
| Stock Option | \$1.23 | 10/29/2018 | | A | | 75,000 | | (9) | 10/29/2028 | Common Stock | 75,000 | \$0 | 75,000 | D | |

Explanation of Responses:

- 1. The option is exercisable to the extent of 15,000 shares on each of February 10, 2012 and February 10, 2013.
- 2. The option is exercisable to the extent of 2,500 shares on each of December 7, 2012 and December 7, 2013.
- 3. The option is exercisable to the extent of 6,250 shares on each of October 4, 2013 and October 4, 2014.
- 4. The option is exercisable to the extent of 8,334 shares on February 18, 2014, and 8,333 shares on each of February 18, 2015 and February 18, 2016.
- 5. The option is exercisable to the extent of 16,667 shares on each of October 23, 2015 and Octobe 23, 2016 and 16,666 shares on October 23, 2017.
- 6. The option is exercisable to the extent of 57,750 shares on December 22, 2015, and 19,250 shares on each of September 4, 2016, September 4, 2017 and September 4, 2018.
- 7. The option is exercisable to the extent of 42,667 shares on each of June 10, 2016 and June 10, 2017, and 42,666 shares on June 10, 2018.
- 8. The option is exercisable to the extent of 41,667 shares on each of June 23, 2017 and June 23, 2018, and 41,666 shares on June 23, 2019.
- 9. The option is exercisable to the extent of 25,000 shares on each of October 29, 2018, October 29, 2019 and October 29, 2020.

/s/ A. Jeffrey Radov

10/30/2018

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.